New shot-based immunotherapy tested against rare cancer
NCT ID NCT07243626
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study tests a new drug called envafolimab, given as a shot, combined with two chemotherapy drugs (doxorubicin and ifosfamide) as a first treatment for advanced soft tissue sarcoma. The goal is to see if this combination works better than chemo alone. About 25 adults with this rare cancer who haven't had prior treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT-TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
RECRUITINGHanzhong, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.